Post-marketing Surveillance of Donepezil Hydrochloride -Investigation of the Factors That Affect Aricept Medication Persistence Rate and the Safety and Efficacy in Patients With Alzheimer's Disease in Clinical Practice

Eisai Co., Ltd.8,662 enrolled

Overview

To investigate the factors that affect Aricept medication persistence rate and the safety and efficacy in patients with Alzheimer's Disease in clinical practice

Study Type

OBSERVATIONAL

Enrollment

8,662

Conditions

Alzheimer's Disease

Interventions

Donepezil HydrochlorideDRUG

Initial dose of 3 mg orally once daily. After 1-2 weeks, dosage increased to 5 mg orally once daily. After 4 or more weeks, dosage increased to 10 mg orally once daily for patients with severe dementia of Alzheimer's type. Dose reduced appropriately according to patient's symptoms.

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion criteria: Patients diagnosed with Alzheimer's Disease and administered Aricept for the first time. Exclusion criteria: Patients with a history of hypersensitivity to any ingredients of Aricept or piperidine derivatives.

Locations (1)

Unnamed facility

Multiple Locations, Japan

Outcomes

Primary Outcomes

Change From Baseline in the Mini-Mental State Examination (MMSE) Score

Time frame: Baseline, Month 3, Month 6, and Month 12

Secondary Outcomes

Investigations on adverse events and adverse drug reactions

Time frame: Baseline and Month 12

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.